Why is spironolactone used to treat hypertension in patients with primary hyperaldosteronism?

Why Spironolactone is Used for Hypertension in Primary Hyperaldosteronism

Spironolactone is used because it directly blocks the mineralocorticoid receptor, thereby antagonizing the pathologic effects of excess aldosterone that drive hypertension, hypokalemia, and cardiovascular damage in primary hyperaldosteronism. 1

Mechanism of Action

Spironolactone functions as a competitive antagonist of the mineralocorticoid receptor in the renal collecting duct 2. In primary aldosteronism (PA), there is autonomous, excessive aldosterone production that causes:

• Sodium retention and volume expansion → hypertension
• Potassium wasting → hypokalemia
• Direct cardiovascular and renal damage independent of blood pressure effects

By blocking the mineralocorticoid receptor, spironolactone:

• Inhibits sodium reabsorption (both directly via Na/K ATPase and indirectly via ENaC channels) 2
• Promotes potassium retention, making it a potassium-sparing diuretic 2
• Reverses the pathologic cardiovascular effects of aldosterone excess 1

Why This Matters: The Mortality and Morbidity Impact

Patients with PA face significantly elevated cardiovascular risks compared to essential hypertensives with identical blood pressure levels 1:

• 2.58-fold increased risk of stroke
• 1.77-fold increased risk of coronary artery disease
• 3.52-fold increased risk of atrial fibrillation
• 2.05-fold increased risk of heart failure
• Increased risk of diabetes (OR 1.33), metabolic syndrome (OR 1.53), and left ventricular hypertrophy (OR 2.29) 1

Spironolactone addresses the root cause by blocking aldosterone's effects, not just lowering blood pressure through non-specific mechanisms 2.

Clinical Indications and Evidence

First-Line Medical Therapy

Spironolactone is the first-line medical treatment for PA 1, 2:

• Bilateral PA (idiopathic hyperaldosteronism): Spironolactone is the primary treatment 1
• Unilateral PA in non-surgical candidates: For patients who refuse surgery or are unsuitable for adrenalectomy 2, 3
• Preoperative preparation: Short-term use before adrenalectomy to control hypertension and hypokalemia 4, 3

Efficacy Data

The evidence demonstrates robust blood pressure and potassium responses:

• Mean reductions of 25% systolic and 22% diastolic blood pressure with spironolactone 50-400 mg/day 2
• 41% achieved blood pressure normalization (<140/90 mmHg) in idiopathic hyperaldosteronism 2
• 48% controlled on spironolactone monotherapy in patients with elevated aldosterone-to-renin ratio 5
• Hypokalemia typically corrects within 3-5 days of initiation 6

Practical Dosing Algorithm

Based on FDA labeling and current guidelines 6, 3:

Initial Dosing

• Standard start: 25 mg once daily for most patients 6
• Higher initial dose: 50 mg daily for severe PA with profound hypokalemia 6
• Lower initial dose: 12.5-25 mg daily for medically complex/frail patients or those on ACE inhibitors/ARBs 6

Titration Strategy

1. Monitor at 2-3 months: Check electrolytes, renal function, and renin 6
2. Increase dose every 8-12 weeks as needed for blood pressure control 6:
   • Increase by 25-50 mg increments
   • Most patients require 50-100 mg/day to achieve renin de-suppression 6
   • FDA-approved range: 100-400 mg/day for PA 3
3. Discontinue potassium supplements at days 2-4 in most cases 6
4. Dietary sodium restriction is critical (<5 g/day salt intake); high-salt diet is the most common reason for apparent non-response 6

Monitoring

• Potassium normalization: Usually within 3-5 days 6
• Full blood pressure effect: May take up to 3 months in severe PA 6
• GFR may decrease initially: This typically represents treatment efficacy, not toxicity, and stabilizes long-term 6

Important Caveats and Side Effects

Anti-androgenic Effects

Because spironolactone also antagonizes androgen receptors and acts as a progesterone receptor agonist 2:

• Gynecomastia: Dose-related, occurring in 7% at <50 mg/day and 52% at >150 mg/day 2
• Sexual dysfunction in men 2
• Menstrual irregularities in women 2

Management strategy:

• Reduce dose to ≤50 mg/day if gynecomastia develops 6
• Switch to eplerenone (more selective MRA, requires 2-3× higher doses) if intolerance persists 1, 2
• Consider amiloride as alternative for hypokalemia control 2

Recent Low-Dose Evidence

A 2026 study showed that doses ≤50 mg daily achieve comparable blood pressure control with significantly fewer adverse effects (especially in men), when combined with other antihypertensives 7. This challenges the traditional high-dose approach and suggests individualized dosing based on tolerance and response.

Hyperkalemia Risk

• More common with eGFR 30-50 mL/min/1.73m² 6
• Consider starting at 25 mg every other day in this population 6
• Avoid concurrent ACE inhibitors/ARBs when possible, or monitor very closely 6

Why Not Just Use Other Antihypertensives?

Standard antihypertensives lower blood pressure but do not address the underlying aldosterone excess that drives the disproportionate cardiovascular morbidity in PA 1. Medical treatment with mineralocorticoid receptor antagonists appears as effective as surgical treatment for controlling hypertension and preventing cardiovascular/renal complications 2, 4, making targeted therapy essential rather than optional.